Company

About Us

Our vision is to provide products that deliver the most complete and actionable genomic data.

10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our Chromium System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.

Executive Management


Board Members

Serge Saxonov Chief Executive Officer, Co-founder

Serge Saxonov co-founded 10x Genomics in 2012 and has served as the CEO since its inception. Prior to 10x Genomics, Serge was VP of Applications at QuantaLife, where he was responsible for building content, driving new applications, and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, Serge was Founding Architect and Director of R&D at 23andMe.

There he defined the initial conception of the product, built many elements of the technology, and drove strategy and execution of R&D functions as the company scaled. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics and biology from Harvard University.

Ben Hindson Chief Scientific Officer, President, Co-founder
Ben Hindson has served as Chief Scientific Officer and Director of 10x Genomics since its founding in 2012. Prior to 10x Genomics, Hindson was Co-founder and Chief Scientific Officer of Quantalife, a privately-held life sciences company that developed and commercialized a droplet digital PCR platform, until its sale to Bio-Rad in 2011. From 2002 to 2008, he served in various positions of increasing responsibility at Lawrence Livermore National Laboratory, in the Chemical and Biological Weapons Non-proliferation Program. He has published extensively in his field and holds many patents for assays and instrumentation. Hindson earned his BSc in Chemistry in 1998 and his PhD in Chemistry in 2001 from Deakin University, Australia.
Paul Conley Board of Directors
Paul Conley has served on the Board of Directors since November of 2013. Dr. Conley leads new investments for Paladin Capital Group while serving as an active Director on many of Paladin’s portfolio company Boards. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology in the HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory. Paul earned a PhD in Computational Physics and an MS in Bioengineering from UCSD, as well as an MS and BS in Mechanical and Aerospace Engineering from the University of Virginia.
Bryan Roberts Board of Directors
Bryan Roberts, Ph.D. has served on the Board of Directors since November of 2013. Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen (NASDAQ: AKAO), Castlight Health (NYSE: CSLT), Ironwood Pharmaceuticals (NASDAQ: IRWD), and Kyruus and also serves on the Board of several other companies, including 10X Genomics, Doctor on Demand, Grand Rounds, Intarcia, and Zeltiq (NASDAQ: ZLTQ). Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), CodeRyte (acquired by 3M), Ikaria (acquired by Madison Dearborn), Illumina (NASDAQ: ILMN), and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and is the only healthcare investor to rank on Forbes’ Midas List six times, 2008 – 2014. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.
Mathai Mammen Board of Directors

Dr. Mammen’s mission is to work with the best research and development professionals in the world to make meaningful medicines that impact the lives of patients, their families and communities.

Prior to joining Janssen in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. He also nucleated a new discovery site in the San Francisco Bay Area.

Prior to Merck, Dr. Mammen led R&D at Theravance, a company he co-founded in 1997 based on his work at Harvard University. Under his leadership, the Theravance team of 200 scientists nominated 31 development candidates in 17 years, created three approved products (Breo®, Anoro®, Vibativ®), two additional assets that have successfully completed Phase 3 studies and a pipeline containing 11 further development-stage compounds in 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).

Dr. Mammen has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

John Stuelpnagel Chairman
John Stuelpnagel has been Chairman of 10x Genomics since August of 2013. In addition, John co-founded and was Executive Chairman of Ariosa from 2010 to 2015 when the company was acquired by Roche. He was also the Chairman of Sequenta from 2010 to 2015 when that company was merged with Adaptive Biotechnologies where he continues as a Member of the Board. Previously, John co-founded Illumina, Inc. and was instrumental in making Illumina one of the most successful life science companies. During his 12 years at Illumina, John served as the company’s first CEO and most recently served as COO. Prior to Illumina, John was a venture capitalist at CW Group. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

10x Genomics Completes $55 Million Series C Financing

[PLEASANTON, CA] March 17, 2016 — 10x Genomics, a company focused on improving and broadening the application of genomic information today announced the close of a $55 million Series C financing. The financing round was led by Fidelity Management & Research Company and included additional new investors Softbank and JS Capital Management LLC, alongside founding investors Venrock, Foresite Capital, and Paladin Capital. The Series C financing will accelerate 10x marketing and sales efforts in support of its GemCode™ and Chromium™ products revolutionizing genome sequencing, while fueling innovative future product development. READ MORE…

fidelity
venrock
foresite-capital
paladin

We invite investors to get a hold of us at IR@10xgenomics.com.

Pleasanton, CA

10x Genomics, Inc.
7068 Koll Center Parkway,
Suite 401
Pleasanton, CA 94566
+1 925 401 7300
+1 800 709 1208

San Francisco, CA

10x Genomics, Inc.
160 Spear Street,
Suite 1130
San Francisco, CA 94105
+1 925 401 7300
+1 800 709 1208

UK, Ireland & Iceland

+44 (0) 7940 434419
justin.cooper@10xgenomics.com

France

+33 (0) 6 37 82 81 40
mickael.ploquin@10xgenomics.com

Austria & Germany

+49 (0) 711 48 96 9090
thorsten.lemker@10xgenomics.com

Sweden, Norway, Finland & Denmark

+46 (0) 735 05 35 06
steve.glavas@10xgenomics.com

Switzerland, & Germany

+41 (0) 79 431 5364
rudi.schlaefli@10xgenomics.com

Italy, Spain & Portugal

+39 (0) 345 3504907
chiara.reggio@10xgenomics.com

Belgium, the Netherlands & Luxembourg

+31 (0) 6 38 70 18 28
guido.vandeworp@10xgenomics.com

Join our expanding network of global distributors!


Australia and New Zealand
Decode Science Pty Ltd
Monash Enterprise Centre
5a Hartnett Close
Mulgrave, Victoria 3170
Australia
Website: www.decodescience.com.au
Email: sales@decodescience.com.au
Korea
DAON BioSciences Inc.
1808, 79 Nonhyeon-ro,
Seocho-gu
Seoul, 06775 Korea
Tel: +82 2 575 6227
Fax: +82 2 575 6228
Website: www.daonbs.com
Email: info@daonbs.com
China
Star Research Technology Ltd.
Room 4D, Building 3
No. 401 Cao Bao Rd
Xuhui District
Shanghai 200233, China
Tel: +86 21 34250079
Fax: +86 21 64398697
Website: www.bio-star.cn
E-mail: marketing@bio-star.cn
Singapore, Malaysia, Thailand, Indonesia, Philippines, Brunei, Vietnam
Research Instruments Pte Ltd
47 Ayer Rajah Crescent #03-12
Republic of Singapore 139947
Tel: +65 6571 0888
Fax: +65 6571 0868
Website: www.ri.com.sg
Email: info@ri.com.sg
Japan
SCRUM Inc.
Kawakoshi Bldg. 3-9-2
Midori, Sumida-ku Tokyo 130-0021
Japan
Tel: +81 (0)3 5625 9711
Fax: +81 (0)3 3634 6333
Website: www.scrum-net.co.jp
Email: webmaster@scrum-net.co.jp
Israel
Pronto Diagnostics, Ltd.
Kiryat Atidim, Building 3, 2nd entrance
Tel Aviv 6158002
POB 58129 Israel
Tel: +972-73-2126155
Fax: +972-73-2126144
Website: www.prontodiagnostics.com
Email: aline@prontodiagnostics.com
Middle East/Africa
Middle East: Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, Palestinian Authorities, Qatar, Saudi Arabia, United Arab Emirates, Yemen
Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of Congo, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, South Africa, Swaziland, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe
Alliance Global FZ – LLC
Office 1610, Concord Tower
Dubai Media City
P.O. Box 500392
Dubai – UAE
Tel: +971 4 375 2-44
Fax: +971 4 429 1376
Website: www.agbl.net
Email: genomics@agbl.net

We invite interested distributors to email info@10xgenomics.com.